Publication:
Multitarget Inhibition of Diabetic Enzymes by Thiazole Carboxylic Acids: Experimental and Computational Approaches

dc.authorscopusid57194462715
dc.authorscopusid57208078744
dc.authorscopusid57193431132
dc.contributor.authorGerni, S.
dc.contributor.authorDemir, Y.
dc.contributor.authorDincer, B.
dc.date.accessioned2025-12-11T00:35:31Z
dc.date.issued2025
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Gerni] Serpil, Department of Chemistry, Atatürk Üniversitesi, Erzurum, Erzurum, Turkey, Department of Pharmacy Services, Ardahan Üniversitesi, Ardahan, Turkey; [Demir] Yeliz, Department of Pharmacy Services, Ardahan Üniversitesi, Ardahan, Turkey; [Dincer] Busra, Department of Pharmacology, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractDiabetes mellitus is a complex metabolic disorder characterized by chronic hyperglycemia, which results from either insulin resistance or insufficient insulin secretion, and is closely associated with numerous microvascular and macrovascular complications. The polyol pathway plays a central role in the onset and progression of diabetic complications, primarily through the actions of two key enzymes: aldose reductase (ALR2) and sorbitol dehydrogenase (SDH), which catalyze critical steps in glucose metabolism under hyperglycemic conditions. In this study, ALR2 and SDH enzymes were purified from sheep kidney tissue, while α-glycosidase was commercially sourced, to evaluate the inhibitory effects of nine novel thiazole-based carboxylic acid derivatives. In vitro enzymatic assays demonstrated that the synthesized compounds exerted potent inhibitory effects on the target enzymes at micromolar concentrations. Notably, compound 5 showed the most pronounced inhibition of ALR2 (K<inf>i</inf>: 0.556 ± 0.102 μM), compound 3 was the most potent inhibitor of SDH (K<inf>i</inf>: 1.890 ± 0.136 μM), and compound 7 exhibited the strongest activity against α-Glu (K<inf>i</inf>: 0.292 ± 0.047 μM). Furthermore, in silico ADMET profiling revealed that the most active compounds possess favorable pharmacokinetic properties, including high gastrointestinal absorption, acceptable solubility, and compliance with key drug-likeness criteria. Additionally, the cytotoxic potential of the most active compounds (3, 5, 6, and 7) was evaluated using the MTT assay on healthy L929 fibroblast cells to assess their safety profiles. These results were corroborated by molecular docking that also revealed the favorable binding interaction in the active sites of the target enzymes. Taken together, the prepared thiazole derivatives are potential lead compounds for discovery of novel antidiabetic drugs for the treatment of diabetes via inhibition of the key enzymes of glucose metabolism. © 2025 Elsevier B.V.en_US
dc.identifier.doi10.1016/j.molliq.2025.128421
dc.identifier.issn0167-7322
dc.identifier.issn1873-3166
dc.identifier.scopus2-s2.0-105014411277
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.molliq.2025.128421
dc.identifier.urihttps://hdl.handle.net/20.500.12712/37671
dc.identifier.volume437en_US
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofJournal of Molecular Liquidsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAldose Reductaseen_US
dc.subjectDiabetesen_US
dc.subjectMolecular Dockingen_US
dc.subjectSorbitol Dehydrogenaseen_US
dc.subjectα-Glucosidaseen_US
dc.titleMultitarget Inhibition of Diabetic Enzymes by Thiazole Carboxylic Acids: Experimental and Computational Approachesen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files